FDA report on BIA-ALCL, explained by Dr. Cohen
Dr. Michael Cohen eases minds regarding FDA report on BIA-ALCL
WMARtv, Wednesday, March 22
On Wednesday, March 22, Dr. Cohen was invited by WMARtv to explain the recent FDA statement that acknowledged a connection between breast implants and the extremely rare possibility of developing BIA-ALCL. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is an extremely rare and highly treatable type of lymphatic cancer that can develop around breast implants (not a cancer of the breast tissue).
Dr. Cohen put patients at ease by explaining that the incidence is so rare that it is not a major concern. The latest statistics from the American Society for Aesthetic Plastic Surgery show that more than 310,000 Americans had breast implant surgery in 2016 alone. The total number of BIA-ALCL cases as reported to the FDA to-date since 1997 is 359 cases. BIA-ALCL appears to develop more frequently in women with textured implants than in women with smooth-surfaced implants.
He went on to say that although BIA-ALCL is extremely rare, he believes that patients should be made aware of all risks prior to undergoing breast implant surgery. Dr. Cohen recommends all women, including those with breast implants, follow their normal routine in medical care and follow up. Should a woman sense any abnormalities or significant changes in her breasts, she should contact her physician immediately.
Dr. Cohen noted that breast implants are among the most studied medical devices available and that both the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery consider them to be safe.
Dr. Cohen would be happy to answer your questions about BIA-ALCA or breast implant surgery. He can be reached at 410.296.0414 or email@example.com.